This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BIO-Europe Spring

€500 savings end in:

  • 00
    Days
  • 00
    Hrs
  • 00
    Mins
  • 00
    Secs
THE SPRINGTIME PARTNERING EVENT
March 18–20, 2024 | Barcelona, SpainMarch 26–27, 2024 | Digital Partnering

Evaxion Biotech A/S

Profile

Evaxion-Biotech A/S (NASDAQ:EVAX) a clinical-stage biotech company. Powered by AI, Evaxion identifies and develops novel immunotherapies for the treatment of various cancers and infectious diseases. Personalised neoantigen vaccines EVX-01 (peptide delivery) Phase 2b for metastatic melanoma EVX-02 (DNA delivery) Phase 1/2a for adjuvant melanoma EVX-03 (APC targeted DNA) IND enabling stage for NSCLC Infectious Disease vaccines EVX-B1 (Staphylococcus aureus) IND enabling EVX-B2 (Neisseria gonorrhoeae) Preclinical EVX-V1 (Cytomegalovirus) Preclinical